Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine ...

NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with ...

Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time.

Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...

The FDA has cleared several oncology products over the past few days, ranging from therapies to diagnostic and imaging tools.

FDA Drug Approvals and Regulatory Updates Drug Pharmacologic class Indication More information Cardiovascular Disease Tryngolza (olezarsen) Apolipoprotein C-III-directed antisense oligonucleotide ...

AstraZeneca ( (GB:AZN)) has issued an update. AstraZeneca has secured U.S. approval for its AKT inhibitor Truqap (capivasertib) in combination with abiraterone and prednisone as the first targeted ...

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 3.4% in the afternoon session after the ...

The Colorectal Cancer Resource & Action Network (CCRAN) today announced that Phase II of its genomic profiling research initiative is underway, continuing its collaboration with Signal49 Research ...

The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP ...

Among the central risk factors in early-stage oncology investing is the distance separating laboratory findings from clinical reality. Onco-Innovations has worked methodically to close that gap. The ...

Longeviti Neuro Solutions, a neurotechnology company focused on advancing innovative solutions that unlock post-operative ...